Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer
- PMID: 15721449
- DOI: 10.1016/j.ygyno.2004.12.001
Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer
Abstract
Background: Angiogenesis is pivotal in the development and progression of ovarian cancer and is an ideal candidate for novel treatment approaches.
Case: A case of advanced, recurrent and refractory serous carcinoma is presented that responded to bevacizumab 15 mg/m2 intravenously every 3 weeks after failing eleventh line cytotoxic chemotherapy and radiation. An objective durable response lasting at least 5 months was documented.
Conclusion: Bevacizumab has activity in epithelial ovarian carcinoma and larger scale trials are indicated.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources